Francisco J. Diaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francisco J. Diaz has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Edward F. Ellerbeck
Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA
6 shared publications - Jose de Leon
Mental Health Research Center, Eastern State Hospital, Lexington, KY
6 shared publications - Ana Paula Cupertino
Department of Surgery, University of Rochester, Rochester, NY 14642, USA
4 shared publications - Evelyn Arana-Chicas
Division of Medical Oncology, Rutgers Cancer Institute, New Brunswick, USA
4 shared publications - Francisco Cartujano-Barrera
Department of Public Health Sciences, University of Rochester Medical Center
4 shared publications - Kristi D. Graves
Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University School of Medicine, 2115 Wisconsin Avenue, NW, Suite 300, Washington, DC 20007, USA
4 shared publications
Latest Publications
- 6 November 2026
- Published by SAGE Publications in Medical Decision Making
An Experimental Design for Confirmatory Clinical Trials Testing the Clinical Utility of an Individualization Rule for 2 Treatments
There is a need for efficient and scientifically sound clinical trials that examine the clinical utility of individualized treatment rules (ITRs) that individualize 2 or more medical treatments. These are trials assessing the effectiveness of the medical decision process taking place in the individualization of the treatments, not the effectiveness of the particular treatments involved. We developed a new experimental design for confirming the superiority of an ITR for 2 treatments over decision processes that ignore patient covariates. The design is built on a new published idea, the ITR’s individualization potential (IP), which compares the average effect on clinical response (AER) of the ITR with that of treatment without individualization (TWI). The AER of a decision approach compares the expected potential response of a patient treated with the treatment recommended by the approach versus the expected response should the patient be treated with the alternative therapy instead. The IP concept implies a novel way of constructing the control group of our design and testing the ITR’s utility. The experimental design provides estimates of the AERs of both the ITR and TWI, which we use to test the individualization potential’s statistical significance. In personalized medicine, one of the 2 treatments is often recommended to a subpopulation of lower-frequency patients more difficult to recruit. Thus, as another innovation, our formulation implies convenient sample size calculations that minimize the number of these patients in the total sample size, contrary to traditional methods of powering clinical trials that usually oversample them. Our design usually needs smaller sample sizes than popular designs and has a more appropriate control group. We illustrate calculating sample sizes for a hypothetical ophthalmology clinical trial.
- 6 November 2026
- Published by SAGE Publications in Medical Decision Making
An Experimental Design for Confirmatory Clinical Trials Testing the Clinical Utility of an Individualization Rule for 2 Treatments
There is a need for efficient and scientifically sound clinical trials that examine the clinical utility of individualized treatment rules (ITRs) that individualize 2 or more medical treatments. These are trials assessing the effectiveness of the medical decision process taking place in the individualization of the treatments, not the effectiveness of the particular treatments involved. We developed a new experimental design for confirming the superiority of an ITR for 2 treatments over decision processes that ignore patient covariates. The design is built on a new published idea, the ITR’s individualization potential (IP), which compares the average effect on clinical response (AER) of the ITR with that of treatment without individualization (TWI). The AER of a decision approach compares the expected potential response of a patient treated with the treatment recommended by the approach versus the expected response should the patient be treated with the alternative therapy instead. The IP concept implies a novel way of constructing the control group of our design and testing the ITR’s utility. The experimental design provides estimates of the AERs of both the ITR and TWI, which we use to test the individualization potential’s statistical significance. In personalized medicine, one of the 2 treatments is often recommended to a subpopulation of lower-frequency patients more difficult to recruit. Thus, as another innovation, our formulation implies convenient sample size calculations that minimize the number of these patients in the total sample size, contrary to traditional methods of powering clinical trials that usually oversample them. Our design usually needs smaller sample sizes than popular designs and has a more appropriate control group. We illustrate calculating sample sizes for a hypothetical ophthalmology clinical trial.
- Open Access
Protocol for the Nutrition OUtReach In Systems of Healthcare (NOURISH) trial: a phase II multicentre, parallel-group randomised controlled trial of medically tailored groceries to prevent malnutrition in transplant and cellular therapy patients
Food insecurity (FI) is a health-related social risk associated with malnutrition, morbidity and increased health expenditures in patients undergoing cancer treatment. Among transplant and cellular therapy (TCT) patients, FI is exacerbated by the financial toxicity associated with treatment costs. The Nutrition OUtReach In Systems of Healthcare (NOURISH) trial is a multicentre randomised controlled trial designed to evaluate the impact of in-clinic delivery of medically tailored groceries (MTGs) on malnutrition risk, clinical outcomes and healthcare costs among food insecure TCT patients. We will recruit 210 food-insecure patients from four sites across the USA to be randomised to receive an MTG bag (intervention) or information on food bank resources (control). We hypothesise that the intervention will decrease malnutrition risk (primary endpoint) by mitigating FI, improving clinical outcomes and reducing healthcare costs while patients are receiving TCT. We will assess malnutrition by using the Global Leader in Malnutrition criteria. A χ2 test will examine the null hypothesis that 100-day malnutrition rates in the intervention and control arms are equal, using a two-sided 0.05 significance level. Trajectories over time of calorie intake and protein intake will be compared using mixed linear models. This study used human participants and was approved through the University of Kansas Medical Center Institutional Review Board (STUDY00161189). All participants provided written informed consent prior to participation in the study. We plan to disseminate results to study participants, participating institutions, peer-reviewed medical journals and national organisations. NCT06802406.
Open AccessProtocol for the Nutrition OUtReach In Systems of Healthcare (NOURISH) trial: a phase II multicentre, parallel-group randomised controlled trial of medically tailored groceries to prevent malnutrition in transplant and cellular therapy patients
Food insecurity (FI) is a health-related social risk associated with malnutrition, morbidity and increased health expenditures in patients undergoing cancer treatment. Among transplant and cellular therapy (TCT) patients, FI is exacerbated by the financial toxicity associated with treatment costs. The Nutrition OUtReach In Systems of Healthcare (NOURISH) trial is a multicentre randomised controlled trial designed to evaluate the impact of in-clinic delivery of medically tailored groceries (MTGs) on malnutrition risk, clinical outcomes and healthcare costs among food insecure TCT patients. We will recruit 210 food-insecure patients from four sites across the USA to be randomised to receive an MTG bag (intervention) or information on food bank resources (control). We hypothesise that the intervention will decrease malnutrition risk (primary endpoint) by mitigating FI, improving clinical outcomes and reducing healthcare costs while patients are receiving TCT. We will assess malnutrition by using the Global Leader in Malnutrition criteria. A χ2 test will examine the null hypothesis that 100-day malnutrition rates in the intervention and control arms are equal, using a two-sided 0.05 significance level. Trajectories over time of calorie intake and protein intake will be compared using mixed linear models. This study used human participants and was approved through the University of Kansas Medical Center Institutional Review Board (STUDY00161189). All participants provided written informed consent prior to participation in the study. We plan to disseminate results to study participants, participating institutions, peer-reviewed medical journals and national organisations. NCT06802406.
- Open Access
- 4 March 2026
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 371 (6) , 551-559
Prevalence and symptoms of post-COVID-19 syndrome in active-duty military personnel
- 4 March 2026
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 371 (6) , 551-559
Open AccessPrevalence and symptoms of post-COVID-19 syndrome in active-duty military personnel
- 2 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 161, 108214
Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: A randomized controlled trial protocol
- 2 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 161, 108214
Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: A randomized controlled trial protocol
- Open Access
Testing the effects of a text message intervention on depression and distress among Latino dementia caregivers: a randomized controlled trial protocol
Background Latino caregivers have poor mental health and access to caregiver support services. Here, we describe the protocol for a randomized controlled trial (RCT) to evaluate the effect of a text message intervention on depression and distress among informal Latino dementia caregivers. We will also assess mechanisms of action. Methods We are enrolling 288 Latino dementia informal caregivers 18 or older into a parallel group RCT. Participants randomized to the intervention group receive a remote, asynchronous, bilingual, bi-directional, six-month texting program focused on dementia education, skill-building and community resources. The control group enters a 7-month waitlist after which they are offered the same intervention as the intervention group. Randomization is stratified by each of the four recruitment sites at a 1:1 ratio. Outcomes (e.g., caregiver depressive symptomatology, distress) are measured via surveys at baseline, 3, 6 and 7 months. Conclusions This RCT addresse two priority areas: eliminating dementia disparities and optimizing caregiver support. Findings have the potential to make clinical and policy-relevant contributions by providing appropriate caregiver support to Latinos in a highly scalable way. Trial registration: ClinicalTrials.gov #NCT06728436. University of Kansas Medical Center STUDY00150585.
Open AccessTesting the effects of a text message intervention on depression and distress among Latino dementia caregivers: a randomized controlled trial protocol
Background Latino caregivers have poor mental health and access to caregiver support services. Here, we describe the protocol for a randomized controlled trial (RCT) to evaluate the effect of a text message intervention on depression and distress among informal Latino dementia caregivers. We will also assess mechanisms of action. Methods We are enrolling 288 Latino dementia informal caregivers 18 or older into a parallel group RCT. Participants randomized to the intervention group receive a remote, asynchronous, bilingual, bi-directional, six-month texting program focused on dementia education, skill-building and community resources. The control group enters a 7-month waitlist after which they are offered the same intervention as the intervention group. Randomization is stratified by each of the four recruitment sites at a 1:1 ratio. Outcomes (e.g., caregiver depressive symptomatology, distress) are measured via surveys at baseline, 3, 6 and 7 months. Conclusions This RCT addresse two priority areas: eliminating dementia disparities and optimizing caregiver support. Findings have the potential to make clinical and policy-relevant contributions by providing appropriate caregiver support to Latinos in a highly scalable way. Trial registration: ClinicalTrials.gov #NCT06728436. University of Kansas Medical Center STUDY00150585.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1) , 6629976
Topical Povidone Iodine 2.5% Versus 5% for Endophthalmitis Prophylaxis During Intravitreal Injections
Purpose: Topical povidone iodine (PI) has been shown to reduce the risk of endophthalmitis following intravitreal injections (IVIs). However, PI is a known ocular irritant and can result in significant eye discomfort. Currently, 5% PI is the most used concentration for ocular surface disinfection prior to IVI. 2.5% PI has been proposed as an alternative IVI preparation to lessen PI‐associated ocular irritation. The purpose of this study is to compare the efficacy of topical PI 2.5% to PI 5% in preventing post‐IVI endophthalmitis at a single academic institution location. Methods: A retrospective chart review was conducted at a single academic institution location of patients receiving IVI from August 1st, 2017, to June 15th, 2022. IVIs were performed using PI 2.5% or PI 5%. PI 5% was applied to the ocular surface 60 s before IVI. PI 2.5% was applied over the ocular surface and then reapplied 4‐5 min later over the injection site and fornices before IVI. Results: A total of 7360 IVIs were performed in 773 patients (473 patients on 2.5% and 300 on 5% PI). 52.0% of IVIs were performed with 2.5% PI ( n = 3826) and 48.0% were performed with 5% PI ( n = 3534). The mean age of patients was 66.8 years for the 2.5% PI group and 69.1 years for the 5% PI subgroup ( p = 0.044). Three cases of endophthalmitis were identified in the 5% PI subgroup (0.08%), and no cases of endophthalmitis were identified in the 2.5% PI subgroup. All cases of endophthalmitis were treated with prompt intravitreal antimicrobial injection. Conclusion: In this retrospective study, we found that 2.5% and 5% PI had similar results in preventing post‐IVI endophthalmitis. This study adds to the literature by further supporting the antiseptic effect of 2.5% PI for IVI. Larger prospective studies are needed to further clarify the antiseptic effect and ocular surface irritation associated with 2.5% PI use.
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1) , 6629976
Open AccessTopical Povidone Iodine 2.5% Versus 5% for Endophthalmitis Prophylaxis During Intravitreal Injections
Purpose: Topical povidone iodine (PI) has been shown to reduce the risk of endophthalmitis following intravitreal injections (IVIs). However, PI is a known ocular irritant and can result in significant eye discomfort. Currently, 5% PI is the most used concentration for ocular surface disinfection prior to IVI. 2.5% PI has been proposed as an alternative IVI preparation to lessen PI‐associated ocular irritation. The purpose of this study is to compare the efficacy of topical PI 2.5% to PI 5% in preventing post‐IVI endophthalmitis at a single academic institution location. Methods: A retrospective chart review was conducted at a single academic institution location of patients receiving IVI from August 1st, 2017, to June 15th, 2022. IVIs were performed using PI 2.5% or PI 5%. PI 5% was applied to the ocular surface 60 s before IVI. PI 2.5% was applied over the ocular surface and then reapplied 4‐5 min later over the injection site and fornices before IVI. Results: A total of 7360 IVIs were performed in 773 patients (473 patients on 2.5% and 300 on 5% PI). 52.0% of IVIs were performed with 2.5% PI ( n = 3826) and 48.0% were performed with 5% PI ( n = 3534). The mean age of patients was 66.8 years for the 2.5% PI group and 69.1 years for the 5% PI subgroup ( p = 0.044). Three cases of endophthalmitis were identified in the 5% PI subgroup (0.08%), and no cases of endophthalmitis were identified in the 2.5% PI subgroup. All cases of endophthalmitis were treated with prompt intravitreal antimicrobial injection. Conclusion: In this retrospective study, we found that 2.5% and 5% PI had similar results in preventing post‐IVI endophthalmitis. This study adds to the literature by further supporting the antiseptic effect of 2.5% PI for IVI. Larger prospective studies are needed to further clarify the antiseptic effect and ocular surface irritation associated with 2.5% PI use.
- 6 August 2024
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 33 (8) , 1355-1375
Measuring the individualization potential of treatment individualization rules: Application to rules built with a new parametric interaction model for parallel-group clinical trials
For personalized medicine, we propose a general method of evaluating the potential performance of an individualized treatment rule in future clinical applications with new patients. We focus on rules that choose the most beneficial treatment for the patient out of two active (nonplacebo) treatments, which the clinician will prescribe regularly to the patient after the decision. We develop a measure of the individualization potential (IP) of a rule. The IP compares the expected effectiveness of the rule in a future clinical individualization setting versus the effectiveness of not trying individualization. We illustrate our evaluation method by explaining how to measure the IP of a useful type of individualized rules calculated through a new parametric interaction model of data from parallel-group clinical trials with continuous responses. Our interaction model implies a structural equation model we use to estimate the rule and its IP. We examine the IP both theoretically and with simulations when the estimated individualized rule is put into practice in new patients. Our individualization approach was superior to outcome-weighted machine learning according to simulations. We also show connections with crossover and N-of-1 trials. As a real data application, we estimate a rule for the individualization of treatments for diabetic macular edema and evaluate its IP.
- 6 August 2024
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 33 (8) , 1355-1375
Measuring the individualization potential of treatment individualization rules: Application to rules built with a new parametric interaction model for parallel-group clinical trials
For personalized medicine, we propose a general method of evaluating the potential performance of an individualized treatment rule in future clinical applications with new patients. We focus on rules that choose the most beneficial treatment for the patient out of two active (nonplacebo) treatments, which the clinician will prescribe regularly to the patient after the decision. We develop a measure of the individualization potential (IP) of a rule. The IP compares the expected effectiveness of the rule in a future clinical individualization setting versus the effectiveness of not trying individualization. We illustrate our evaluation method by explaining how to measure the IP of a useful type of individualized rules calculated through a new parametric interaction model of data from parallel-group clinical trials with continuous responses. Our interaction model implies a structural equation model we use to estimate the rule and its IP. We examine the IP both theoretically and with simulations when the estimated individualized rule is put into practice in new patients. Our individualization approach was superior to outcome-weighted machine learning according to simulations. We also show connections with crossover and N-of-1 trials. As a real data application, we estimate a rule for the individualization of treatments for diabetic macular edema and evaluate its IP.
- Open Access
- 30 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (4) , e0297749
pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model
Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatment. The therapeutic limitations of GEM are primarily due to poor bioavailability and the development of chemoresistance resulting from the addiction of mutant-K-RAS/AKT/ERK signaling-mediated desmoplastic barriers with a hypoxic microenvironment. Several new therapeutic approaches, including nanoparticle-assisted drug delivery, are being investigated by us and others. This study used pH-responsive nanoparticles encapsulated ERK inhibitor (SCH772984) and surface functionalized with tumor-penetrating peptide, iRGD, to target PDAC tumors. We used a small molecule, SCH772984, to target ERK1 and ERK2 in PDAC and other cancer cells. This nanocarrier efficiently released ERKi in hypoxic and low-pH environments. We also found that the free-GEM, which is functionally weak when combined with nanoencapsulated ERKi, led to significant synergistic treatment outcomes in vitro and in vivo. In particular, the combination approaches significantly enhanced the GEM effect in PDAC growth inhibition and prolonged survival of the animals in a genetically engineered KPC (LSL-KrasG12D/+/LSL-Trp53R172H/+/Pdx-1-Cre) pancreatic cancer mouse model, which is not observed in a single therapy. Mechanistically, we anticipate that the GEM efficacy was increased as ERKi blocks desmoplasia by impairing the production of desmoplastic regulatory factors in PDAC cells and KPC mouse tumors. Therefore, 2nd generation ERKi (SCH 772984)-iRGD-pHNPs are vital for the cellular response to GEM and denote a promising therapeutic target in PDAC with mutant K-RAS.
- 30 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (4) , e0297749
Open AccesspH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model
Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatment. The therapeutic limitations of GEM are primarily due to poor bioavailability and the development of chemoresistance resulting from the addiction of mutant-K-RAS/AKT/ERK signaling-mediated desmoplastic barriers with a hypoxic microenvironment. Several new therapeutic approaches, including nanoparticle-assisted drug delivery, are being investigated by us and others. This study used pH-responsive nanoparticles encapsulated ERK inhibitor (SCH772984) and surface functionalized with tumor-penetrating peptide, iRGD, to target PDAC tumors. We used a small molecule, SCH772984, to target ERK1 and ERK2 in PDAC and other cancer cells. This nanocarrier efficiently released ERKi in hypoxic and low-pH environments. We also found that the free-GEM, which is functionally weak when combined with nanoencapsulated ERKi, led to significant synergistic treatment outcomes in vitro and in vivo. In particular, the combination approaches significantly enhanced the GEM effect in PDAC growth inhibition and prolonged survival of the animals in a genetically engineered KPC (LSL-KrasG12D/+/LSL-Trp53R172H/+/Pdx-1-Cre) pancreatic cancer mouse model, which is not observed in a single therapy. Mechanistically, we anticipate that the GEM efficacy was increased as ERKi blocks desmoplasia by impairing the production of desmoplastic regulatory factors in PDAC cells and KPC mouse tumors. Therefore, 2nd generation ERKi (SCH 772984)-iRGD-pHNPs are vital for the cellular response to GEM and denote a promising therapeutic target in PDAC with mutant K-RAS.
- Open Access
- 14 July 2022
- Published by Universidad Nacional de Colombia in Revista Colombiana de Estadística
- Vol. 45 (2) , 275-300
Measuring Individual Benefits of Medical Treatments Using Longitudinal Hospital Data with Non-Ignorable Missing Responses Caused by Patient Discharge: Application to the Study of Benefits of Pain Management Post Spinal Fusion
Electronic health records (EHR) provide valuable resources for longitudinal studies and understanding risk factors associated with poor clinical outcomes. However, they may not contain complete follow-ups, and the missing data may not be at random since hospital discharge may depend in part on expected but unrecorded clinical outcomes that occur after patient discharge. These non-ignorable missing data requires appropriate analysis methods. Here, we are interested in measuring and analyzing individual treatment benefits of medical treatments in patients recorded in EHR databases. We present a method for predicting individual benefits that handles non-ignorable missingness due to hospital discharge. The longitudinal clinical outcome of interest is modeled simultaneously with the hospital length of stay using a joint mixed-effects model, and individual benefits are predicted through a frequentist approach: the empirical Bayesian approach. We illustrate our approach by assessing individual pain management benefits to patients who underwent spinal fusion surgery. By calculating sample percentiles of empirical Bayes predictors of individual benefits, we examine the evolution of individual benefits over time. We additionally compare these percentiles with percentiles calculated with a Monte Carlo approach. We showed that empirical Bayes predictors of individual benefits do not only allow examining benefits in specific patients but also reflect overall population trends reliably.
- 14 July 2022
- Published by Universidad Nacional de Colombia in Revista Colombiana de Estadística
- Vol. 45 (2) , 275-300
Open AccessMeasuring Individual Benefits of Medical Treatments Using Longitudinal Hospital Data with Non-Ignorable Missing Responses Caused by Patient Discharge: Application to the Study of Benefits of Pain Management Post Spinal Fusion
Electronic health records (EHR) provide valuable resources for longitudinal studies and understanding risk factors associated with poor clinical outcomes. However, they may not contain complete follow-ups, and the missing data may not be at random since hospital discharge may depend in part on expected but unrecorded clinical outcomes that occur after patient discharge. These non-ignorable missing data requires appropriate analysis methods. Here, we are interested in measuring and analyzing individual treatment benefits of medical treatments in patients recorded in EHR databases. We present a method for predicting individual benefits that handles non-ignorable missingness due to hospital discharge. The longitudinal clinical outcome of interest is modeled simultaneously with the hospital length of stay using a joint mixed-effects model, and individual benefits are predicted through a frequentist approach: the empirical Bayesian approach. We illustrate our approach by assessing individual pain management benefits to patients who underwent spinal fusion surgery. By calculating sample percentiles of empirical Bayes predictors of individual benefits, we examine the evolution of individual benefits over time. We additionally compare these percentiles with percentiles calculated with a Monte Carlo approach. We showed that empirical Bayes predictors of individual benefits do not only allow examining benefits in specific patients but also reflect overall population trends reliably.